MIM
SGMT icon

MetLife Investment Management’s Sagimet Biosciences SGMT Stock Holding History

MetLife Investment Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$276K Buy
+35,682
New +$243K ﹤0.01% 2254

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

MetLife Investment Management's SGMT Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 35,682 shares worth $276K. The stake represents ﹤0.01% of the portfolio and ranks #2254 among its holdings.

122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • MetLife Investment Management held 35,682 shares of Sagimet Biosciences worth $276K as of Q2 2026.
  • Sagimet Biosciences was a new MetLife Investment Management position in Q2 2026.
  • Sagimet Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2254 holding.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.